Micelle formulation of hexadecyloxypropyl-cidofovir (HDP-CDV) as an intravitreal long-lasting delivery system

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 89, Issue , 2015, Pages 271-279

  Ma, Feiyan ^a   Nan, Kaihui ^a   Lee, Suna ^a   Beadle, James R ^b   Hou, Huiyuan ^a   Freeman, William R ^a   Hostetler, Karl Y ^b   Cheng, Lingyun ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Cidofovir; Guinea pig eye; Herpes simplex virus 1 retinitis; Intravitreal drug delivery; Lipid prodrug; Micelles formulation; Rabbit eye

Indexed keywords

BRINCIDOFOVIR; ANTIVIRUS AGENT; CYTOSINE; DELAYED RELEASE FORMULATION; MICELLE; PHOSPHONIC ACID DERIVATIVE; PRODRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CRITICAL MICELLE CONCENTRATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; HERPES SIMPLEX VIRUS 1; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; INTRAOCULAR PRESSURE; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MICELLIZATION; NONHUMAN; PHYSICAL CHEMISTRY; RETINITIS; SCANNING ELECTRON MICROSCOPY; STUDY DESIGN; SUSTAINED DRUG RELEASE; ZETA POTENTIAL; ADMINISTRATION AND DOSAGE; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; GUINEA PIG; HALF LIFE TIME; HERPES SIMPLEX; INTRAVITREAL DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; MICELLE; PROCEDURES; RABBIT; RETINA; VIROLOGY; VITREOUS BODY;

ANIMALS; ANTIVIRAL AGENTS; CHEMISTRY, PHARMACEUTICAL; CYTOSINE; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; GUINEA PIGS; HALF-LIFE; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; INTRAVITREAL INJECTIONS; MICELLES; ORGANOPHOSPHONATES; PRODRUGS; RABBITS; RETINA; VITREOUS BODY;

EID: 84920126763     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2014.12.010     Document Type: Article

References (39)

1. H. Izzedine, V. Launay-Vacher, and G. Deray Antiviral drug-induced nephrotoxicity Am. J. Kidney Diseases: Official J. Natl. Kidney Found. 45 2005 804 817
2. T. Jacobsen, and N. Sifontis Drug interactions and toxicities associated with the antiviral management of cytomegalovirus infection Am. J. Health Syst. Pharm. 67 2010 1417 1425
3. J. Chhablani, A. Nieto, and H.Y. Hou Oxidized porous silicon particles covalently grafted with daunorubicin as a sustained intraocular drug delivery system Invest. Ophthalmol. Vis. Sci. 54 2013 1268 1279
4. H.Y. Hou, A. Nieto, F.Y. Ma, W.R. Freeman, M.J. Sailor, and L.Y. Cheng Tunable sustained intravitreal drug delivery system for daunorubicin using oxidized porous silicon J. Controlled Release 178 2014 46 54
5. M. Merodio, J.M. Irache, F. Valamanesh, and M. Mirshahi Ocular disposition and tolerance of ganciclovir-loaded albumin nanoparticles after intravitreal injection in rats Biomaterials 23 2002 1587 1594
6. H. Koo, H. Moon, and H. Han The movement of self-assembled amphiphilic polymeric nanoparticles in the vitreous and retina after intravitreal injection Biomaterials 33 2012 3485 3493
7. L. Cheng, K.Y. Hostetler, and J. Lee Characterization of a novel intraocular drug-delivery system using crystalline lipid antiviral prodrugs of ganciclovir and cyclic cidofovir Invest. Ophthalmol. Vis. Sci. 45 2004 4138 4144
8. L. Cheng, K.Y. Hostetler, and N. Valiaeva Intravitreal crystalline drug delivery for intraocular proliferation diseases Invest. Ophthalmol. Vis. Sci. 51 2010 474 481
9. F.M. Rahhal, J.F. Arevalo, E. Chavez de la Paz, D. Munguia, S.P. Azen, and W.R. Freeman Treatment of cytomegalovirus retinitis with intravitreous cidofovir in patients with AIDS. A preliminary report Ann. Intern. Med. 125 1996 98 103
10. I. Taskintuna, F.M. Rahhal, and J.F. Arevalo Low-dose intravitreal cidofovir (HPMPC) therapy of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome Ophthalmology 104 1997 1049 1057
11. M. Nicolo, F. Nasciuti, S. Lai, D. Ghiglione, L. Borgia, and G. Calabria Intravitreal triamcinolone acetonide as primary treatment for diffuse diabetic macular edema: a prospective noncomparative interventional case series Eur. J. Ophthalmol. 16 2006 129 133
12. L. Cheng, K.Y. Hostetler, and S. Chaidhawangul Intravitreal toxicology and duration of efficacy of a novel antiviral lipid prodrug of ganciclovir in liposome formulation Invest. Ophthalmol. Vis. Sci. 41 2000 1523 1532
13. L.Y. Cheng, M.E. Rivero, and C.R. Garcia Evaluation of intraocular pharmacokinetics and toxicity of prinomastat (AG3340) in the rabbit J. Ocul. Pharmacol. Ther. 17 2001 295 304
14. I.A. Falkenstein, L. Cheng, and T.R. Jones Intraocular properties of a repository urokinase receptor antagonist a36 Peptide in rabbits Curr. Eye Res. 35 2010 742 750
15. F.K.P. Sutter, and M.C. Gillies Pseudo-endophthalmitis after intravitreal injection of triamcinolone Br. J. Ophthalmol. 87 2003 972 974
16. J.R. Beadle, C. Hartline, and K.A. Aldern Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro Antimicrob. Agents Chemother. 46 2002 2381 2386
17. K.Y. Hostetler, S. Rought, K.A. Aldern, J. Trahan, J.R. Beadle, and J. Corbeil Enhanced antiproliferative effects of alkoxyalkyl esters of cidofovir in human cervical cancer cells in vitro Mol. Cancer Ther. 5 2006 156 159
18. H. Wang, J. Chhablani, and W.R. Freeman Intraocular safety and pharmacokinetics of hexadecyloxypropyl-cidofovir (HDP-CDV) as a long-lasting intravitreal antiviral drug Invest. Ophthalmol. Vis. Sci. 52 2011 9391 9396
19. K.G. Furton, and A. Norelus Determining the critical micelle concentration of aqueous surfactant solutions - using a novel colorimetric method J. Chem. Educ. 70 1993 254 257
20. J.S. Kim, J.R. Beadle, and W.R. Freeman A novel cytarabine crystalline lipid prodrug: hexadecyloxypropyl cytarabine 3′,5′-cyclic monophosphate for proliferative vitreoretinopathy Mol. Vision 18 2012 1907 1917
21. L. Cheng, K.Y. Hostetler, and S. Chaidhawangul Treatment or prevention of herpes simplex virus retinitis with intravitreally injectable crystalline 1-O-hexadecylpropanediol-3-phospho-ganciclovir Invest. Ophthalmol. Vis. Sci. 43 2002 515 521
22. L. Cheng, K.Y. Hostetler, and S. Chaidhawangul Treatment of herpes retinitis in an animal model with a sustained delivery antiviral drug, liposomal 1-O-octadecyl-SN-glycerol-3-phosphonoformate Retina 19 1999 325 331
23. C.R. Group, D.F. Martin, and M.G. Maguire Ranibizumab and bevacizumab for neovascular age-related macular degeneration N. Engl. J. Med. 364 2011 1897 1908
24. N. Li, C. Zhuang, M. Wang, X. Sun, S. Nie, and W. Pan Liposome coated with low molecular weight chitosan and its potential use in ocular drug delivery Int. J. Pharm. 379 2009 131 138
25. R.C. Nagarwal, S. Kant, P.N. Singh, P. Maiti, and J.K. Pandit Polymeric nanoparticulate system: a potential approach for ocular drug delivery J. Controlled Release 136 2009 2 13
26. Y. Gao, Y. Sun, F. Ren, and S. Gao PLGA-PEG-PLGA hydrogel for ocular drug delivery of dexamethasone acetate Drug Dev. Ind. Pharm. 36 2010 1131 1138
27. B.G. Short Safety evaluation of ocular drug delivery formulations: techniques and practical considerations Toxicol. Pathol. 36 2008 49 62
28. H. Kim, S.B. Robinson, and K.G. Csaky Investigating the movement of intravitreal human serum albumin nanoparticles in the vitreous and retina Pharm. Res. 26 2009 329 337
29. H. Davson, and C.P. Luck Chemistry and rate of turnover of the ocular fluids of the bush baby (Galago-Crassicaudatus-Agisymbanus) J. Physiol. - London 145 1959 433
30. H. Moseley, W.S. Foulds, D. Allan, and P.M. Kyle Routes of clearance of radioactive water from the rabbit vitreous Br. J. Ophthalmol. 68 1984 145 151
31. K. Henry, H. Cantrill, C. Fletcher, B.J. Chinnock, and H.H. Balfour Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS Am. J. Ophthalmol. 103 1987 17 23
32. K. Cundy, G. Lynch, J. Shaw, M. Hitchcock, and W. Lee Distribution and metabolism of intravitreal cidofovir and cyclic HPMPC in rabbits Curr. Eye Res. 15 1996 569 576
33. D.R. Dolnak, D. Munguia, and C.A. Wiley Lack of retinal toxicity of the anticytomegalovirus drug (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine Invest. Ophthalmol. Vis. Sci. 33 1992 1557 1563
34. I. Taskintuna, F.M. Rahhal, E.V. Capparelli, K.C. Cundy, and W.R. Freeman Intravitreal and plasma cidofovir concentrations after intravitreal and intravenous administration in AIDS patients with cytomegalovirus retinitis J. Ocul. Pharmacol. Ther. 14 1998 147 151
35. L.Y. Cheng, K.Y. Hostetler, and M. Toyoguchi Ganciclovir release rates in vitreous from different formulations of 1-O-hexadecylpropanediol-3-phospho-ganciclovir J. Ocul. Pharmacol. Ther. 19 2003 161 169
36. D.A. Jabs, A. Ahuja, M. Van Natta, A. Lyon, S. Srivastava, and S. Gangaputra Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: five-year outcomes Ophthalmology 117 2010 2152 2161 e2
37. F.J. Palella Jr., K.M. Delaney, and A.C. Moorman Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators N. Engl. J. Med. 338 1998 853 860
38. W.R. Freeman New developments in the treatment of CMV retinitis Ophthalmology 103 1996 999 1000
39. W. De Cian Cidofovir, a new addition to the available therapies against cytomegalovirus M. Scholz, H.F. Rabenau, H.W. Doerr, J. Cinatl Jr CMV-Related Immunopathology vol. 21 1998 Monogr Virol Basel, Karger 215 228